Status:
UNKNOWN
Pharmacogenomics Studies of Antidepressants
Lead Sponsor:
National Cheng-Kung University Hospital
Collaborating Sponsors:
Department of Health, Executive Yuan, R.O.C. (Taiwan)
Conditions:
Major Depressive Disorder
Antidepressive Agents
Eligibility:
All Genders
16-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to establish the clinical effectiveness of antidepressants by pharmacogenomic approach, and to determine the levels of inflammatory factors between the baseline and the en...
Eligibility Criteria
Inclusion
- Age: 16-65 years old
- Signed informed consent by patient or legal representative
- Hamilton Rating Scale for Depression (HDRS) scores ≥ 16
- A diagnosis of MDD according to DSM-IV criteria made by a specialist in psychiatry
Exclusion
- monoamine oxidase inhibitor or antidepressant treatment within two weeks prior to entering the study
- A DSM-IV diagnosis of substance abuse within the past three months
- An organic mental disease, mental retardation or dementia
- A serious surgical condition or physical illness
- Patients who were pregnant or breastfeeding
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2011
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01204086
Start Date
March 1 2007
End Date
February 1 2011
Last Update
September 17 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cheng-Kung University Hospital
Tainan, Taiwan, 704